Based on these studies, there are some evidence supporting the use of a panel of IC receptors/ligands as prognostic biomarkers in severe COVID-19 patients; this panel could include upregulations of PD-1, CTLA-4, TIM-3, PD-L1, Gal-3, and Gal-9. The gene discussed is PDCD1; the disease is COVID-19.